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As to the bronchodilating action of tetrahydroisoquinolfries, Iwasasva and Kiyomoto
(1) reported that the chemical structure essential for full manifestation of the activity should include 1.2,3,4-tetrahydroisoquinoline nucleus, t%%o free hydroxyl groups at position 6 and 7, and arylmethyl group at position 1. They also demonstrated that 3,4,5-trimethoxybenzyl analogue was the most active among arylmethyl groups tested. The contribution of hydroxyl groups to the bronchodilating action of 1,1,3,4-tetrahydroisoquinoline derivatives possessing 3,4,5-trimethoxybenzyl group at position 1, however, remained unclear.
The present experiments were performed to investigate the bronchodilating activities of 7-hydroxyl, 5,7-dihydroxyl, 5,6,7-trihydroxyl and 6,7,8-trihydroxyl groups of (3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (TMI) in anesthetized cats. To determine ,3_-adrenoceptor selectivities of these compounds, effects on the cardiovascular system were also studied. Isoproterenol ([so) and 6,7-dihydroxy-TMI (AQ-110 (1-8))
were included for comparative purposes.
MATERIALS AND METHODS
Cats of either sex, weighing 1. Geometric mean ED values with 95 ° confidence intervals (C.I.) (9) were calculated for the TMI derivatives and compared to the calculated ED value for Iso to obtain the relative a 50 % inhibition (ED50), Iso was the most potent and the potency was followed by these of AQ-110, II, III, IV and I in decreasing order. Of the five TMI derivatives, AQ-110 exhibited the greatest potency, while the activity of I was weakest: the potencies of AQ-1 10 and I were 1/2.6 and 1/36 that of Iso, respectively.
It was also evident that the bronchodilating actions of the TMI derivatives continued for considerably longer than that of Iso (Fig. 3) . Among the TMI derivatives, I and 11 produced longer-lasting effects than AQ-110, III and IV. Under the condition in which the same peak response (approx. 75 % of control) was elicited, the half-duration (see the legend in Table 2 ) was approx. 40 min for I and 11, 20 min for AQ-110, III and IV, and less than 10 min for Iso.
Effects on heart rate: Fig. 2 -B represents dose-response curves for peak increases in heart rate obtained for Iso and the TMI derivatives. Similar to the effects on bronchodilation, the dose-response curves of AQ-110, 11, III, IV and Iso were in parallel, but the curve for I was obviously less steep than that for Iso (P<0.01).
As shown in Fig. 2 -B, the positive chronotropic action of Iso was the strongest, followed by AQ-110, 11, III, IV and I in that decreasing order. At doses which were necessary for increasing the heart rate by 15 beats/ min (HR,5), the potencies of AQ-110 and I were 1/4.9 and 1/350 that of Iso, respectively.
Time course for the positive chronotropic action of each compound was similar to that for the bronchodilating effect described above. ED values and activity ratios: Table I summarizes the ED values and activity ratios of Iso and the TMI derivatives in regard to inhibition of the 5-HT-induced bronchocon striction, increase in heart rate and decrease in diastolic pressure in anesthetized cats. Activity ratios of the TMI derivatives, i.e., the ratios of the bronchodilating activity to the positive chronotropic or depressor activity, were expressed as values relative to the activity ratio for
Iso. It was demonstrated in Table 1 that the TMI derivatives exerted their actions more selectively on the bronchial system than on heart rate when compared with Iso, and I was the most selective. The activity ratios of I was approx. 9, whereas those of the other TMI derivatives were approx. 2. Separation between bronchodilating and depressor actions were also evident in I, 11 and AQ-110: the activity ratios of these compounds were 2-3 times that of Iso. On the other hand, III and IV had no significant selectivity on bronchodilating and depressor actions as compared with Iso.
Intraduoclenal study Table 2 represents the bronchodilating activities of Iso and the TMI derivatives, ad ministered into the duodenum in anesthetized cats. As shown in Table 2 , doses required for reducing the 5-HT-induced bronchoconstriction by approx. 70'/ of control were 100, 20, 20, 10, 30, 100 ,tg/kg for [so, AQ-110, 1, 11, lli and IV, respectively. Thus, II exhibited the most potent bronchodilating action, the potency of which was approx. 10 times that of a) Half-duration was defined as the period from the onset to the point of half recovery from its peak response. b) Dose which reduced the 5-HT-induced bronchoconstriction to the same extent in intraduodenal administration was calculated from dose-response curves in Fig. 2 -A.
Iso. It was also found that time required for the peak activity was 15 min for Iso, 30 min for AQ-110, III and IV, 45 min for I and 60 min for II. On the other hand, the bron chodilating effects of I and II were considerably long-lasting and their half-durations were more than 210 min ( Table 2 ). The half-durations for AQ-110, III and IV were 120-150 min, while that for Iso was 75 min. The maximum increase in heart rate, measured simultaneously with the bronchodilating action, were 57.6=8. As shown in the present experiments, bronchodilating actions as well as positive chrono tropic and depressor effects of the TM I derivatives were all inhibited by pretreatment with propranolol, suggesting that these compounds were acting as (3-sympathomimetics. Iwasawa and Kiyomoto (1) have postulated that two hydroxyl groups at position 6 and 7 were neces sary for full manifestation of j3-sympathomimetic action of the TMI derivatives. The present results, however, indicate that hydroxyl group at position 6 is not necessarily required, since 7-hydroxyl and 5,7-dihydroxyl analogues also exhibited the (3-sympathomimetic activity, although their potencies were lower than that of 6,7-dihydroxyl analogue.
It is worthy of notice that the TMI derivatives, as compared to Iso, exerted their actions more selectively on broncheal smooth muscle than on heart rate. This selectivity was most marked for I among the TMI derivatives tested. Therefore, it is inferred that the TMI derivatives are classified as ,32-sympathomimetics (11, 12) . On the other hand, the dose response curve for I on either bronchodilating or positive chronotropic action was not parallel to those of the other TMI derivatives and Iso. Thus, as compared to the other TMI derivatives, different pharmacological mechanisms may be involved in the action of I.
It is of interest that the bronchodilating activities of I, lI and AQ-1 10 were 2-3 times as potent as their depressor activities and these actions can be differentiated. It has been reported that the bronchodilating activity of phenylethanolamine derivatives is reduced to 1/10-1 /100 when hydroxyl groups of the catechol type were transformed to the resorcinol type, as represented by orciprenaline or terbutaline (13) (14) (15) (16) (17) . In the case of TMI derivatives, however, the transformation from catechol type (AQ-1 10) to resorcinol type (II) did not cause any significant decrease in bronchodilating activity. On the other hand, it has been shown that the duration of the effect of resorcinol derivatives was longer than that of catechol derivatives (14, 15) and that the former compounds were less sensitive to catechol-O-methyltransferase (COMT) than the latter (18) . The bronchodilating action of .1 (monohydroxy analogue) and II (resorcinol type) was also longer-lasting, suggesting that these compounds are little metabolized by COMT.
When administered into the duodenum, I and If produced a significantly longer bron chodilating action. In addition, the i.d./i.v. dose ratios of these compounds were smaller than those of the other TM I derivatives. These results suggest that I and II exhibit a greater absorption efficiency or intraduodenal bioavailability than the other compounds tested.
